{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:36:55Z","timestamp":1791599815938,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.peptides.2023.171051","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T02:11:50Z","timestamp":1688609510000},"page":"171051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["The present and future of synthetic orexin receptor agonists"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-6292","authenticated-orcid":false,"given":"Tsuyoshi","family":"Saitoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.peptides.2023.171051_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.peptides.2023.171051_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrn3837","article-title":"The role of orexin in motivated behaviours","volume":"15","author":"Sakurai","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.peptides.2023.171051_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.peptides.2023.171051_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"issue":"9197","key":"10.1016\/j.peptides.2023.171051_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.peptides.2023.171051_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2174\/156802608784936746","article-title":"Orexin receptor antagonists: medicinal chemistry and therapeutic potential","volume":"8","author":"Roecker","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"issue":"8","key":"10.1016\/j.peptides.2023.171051_bib7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cmdc.201000132","article-title":"Orexin receptor antagonists: a new concept in CNS disorders?","volume":"5","author":"Gatfield","year":"2010","journal-title":"ChemMedChem"},{"issue":"17","key":"10.1016\/j.peptides.2023.171051_bib8","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.bmcl.2013.06.057","article-title":"Selective orexin receptor antagonists","volume":"23","author":"Lebold","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.peptides.2023.171051_bib9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1517\/13543776.2014.978859","article-title":"Orexin receptor antagonists\u2013a patent review (2010 to August 2014)","volume":"24","author":"Boss","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"issue":"29","key":"10.1016\/j.peptides.2023.171051_bib10","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.2174\/1568026616666150929111607","article-title":"Orexin receptor antagonists: historical perspectives and future opportunities","volume":"16","author":"Andrews","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"2","key":"10.1016\/j.peptides.2023.171051_bib11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.5b00832","article-title":"Orexin receptor antagonists: new therapeutic agents for the treatment of insomnia","volume":"59","author":"Roecker","year":"2016","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.peptides.2023.171051_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/13543776.2017.1344221","article-title":"Orexin research: patent news from 2016","volume":"27","author":"Boss","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"issue":"14","key":"10.1016\/j.peptides.2023.171051_bib13","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.peptides.2023.171051_bib14","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","article-title":"Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist","volume":"58","author":"Yoshida","year":"2015","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.peptides.2023.171051_bib15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The quest for the best dual orexin receptor antagonist (Daridorexant) for the treatment of insomnia disorders","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"issue":"20","key":"10.1016\/j.peptides.2023.171051_bib16","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of non-peptide, selective orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.peptides.2023.171051_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.1c00626","article-title":"Discovery of TAK-925 as a potent, selective, and brain-penetrant orexin 2 receptor agonist","volume":"13","author":"Fujimoto","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.peptides.2023.171051_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"17","key":"10.1016\/j.peptides.2023.171051_bib19","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.peptides.2023.171051_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.peptides.2023.171051_bib21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI71017","article-title":"Orexin neurons suppress narcolepsy via 2 distinct efferent pathways","volume":"124","author":"Hasegawa","year":"2014","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.peptides.2023.171051_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.peptides.2023.171051_bib23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.peptides.2023.171051_bib24","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1523\/JNEUROSCI.5560-03.2004","article-title":"Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat","volume":"24","author":"Beuckmann","year":"2004","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.peptides.2023.171051_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.peptides.2023.171051_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"issue":"1\u20132","key":"10.1016\/j.peptides.2023.171051_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-8993(99)01336-0","article-title":"Distribution of orexin neurons in the adult rat brain","volume":"827","author":"Nambu","year":"1999","journal-title":"Brain Res"},{"issue":"19","key":"10.1016\/j.peptides.2023.171051_bib29","doi-asserted-by":"crossref","first-page":"RC168","DOI":"10.1523\/JNEUROSCI.21-19-j0003.2001","article-title":"Orexin (hypocretin) neurons contain dynorphin","volume":"21","author":"Chou","year":"2001","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.peptides.2023.171051_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062391","article-title":"Neurotensin co-expressed in orexin-producing neurons in the lateral hypothalamus plays an important role in regulation of sleep\/wakefulness states","volume":"8","author":"Furutani","year":"2013","journal-title":"PLoS One"},{"issue":"36","key":"10.1016\/j.peptides.2023.171051_bib31","doi-asserted-by":"crossref","first-page":"12437","DOI":"10.1523\/JNEUROSCI.0706-12.2012","article-title":"Optogenetic probing of fast glutamatergic transmission from hypocretin\/orexin to histamine neurons in situ","volume":"32","author":"Schone","year":"2012","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.peptides.2023.171051_bib32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.neuroscience.2008.02.058","article-title":"Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse","volume":"153","author":"Takahashi","year":"2008","journal-title":"Neuroscience"},{"issue":"23","key":"10.1016\/j.peptides.2023.171051_bib33","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.peptides.2023.171051_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0006-291X(03)00299-7","article-title":"Regulation of orexin neurons by the monoaminergic and cholinergic systems","volume":"303","author":"Yamanaka","year":"2003","journal-title":"Biochem Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.peptides.2023.171051_bib35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0896-6273(03)00331-3","article-title":"Hypothalamic orexin neurons regulate arousal according to energy balance in mice","volume":"38","author":"Yamanaka","year":"2003","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.peptides.2023.171051_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuron.2005.03.010","article-title":"Input of orexin\/hypocretin neurons revealed by a genetically encoded tracer in mice","volume":"46","author":"Sakurai","year":"2005","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.peptides.2023.171051_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/cne.20859","article-title":"Afferents to the orexin neurons of the rat brain","volume":"494","author":"Yoshida","year":"2006","journal-title":"J. Comp. Neurol."},{"issue":"3","key":"10.1016\/j.peptides.2023.171051_bib38","doi-asserted-by":"crossref","first-page":"R581","DOI":"10.1152\/ajpregu.00671.2002","article-title":"Attenuated defense response and low basal blood pressure in orexin knockout mice","volume":"285","author":"Kayaba","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.peptides.2023.171051_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2009.01.022","article-title":"Orexin neurons in the hypothalamus mediate cardiorespiratory responses induced by disinhibition of the amygdala and bed nucleus of the stria terminalis","volume":"1262","author":"Zhang","year":"2009","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.peptides.2023.171051_bib40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0960-894X(01)00043-9","article-title":"Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor","volume":"11","author":"Darker","year":"2001","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"1","key":"10.1016\/j.peptides.2023.171051_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0960-894X(02)00851-X","article-title":"Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B","volume":"13","author":"Asahi","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.peptides.2023.171051_bib42","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/jm030982t","article-title":"Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands","volume":"47","author":"Lang","year":"2004","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.peptides.2023.171051_bib43","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1021\/ml400333a","article-title":"Truncated orexin peptides: structure-activity relationship studies","volume":"4","author":"German","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.peptides.2023.171051_bib44","first-page":"565","article-title":"Solution structure of human orexin-A: regulator of appetite and wakefulness","volume":"37","author":"Kim","year":"2004","journal-title":"J. Biochem Mol. Biol."},{"issue":"7","key":"10.1016\/j.peptides.2023.171051_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/psc.747","article-title":"Orexin-A is composed of a highly conserved C-terminal and a specific, hydrophilic N-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor","volume":"12","author":"Takai","year":"2006","journal-title":"J. Pept. Sci."},{"issue":"3","key":"10.1016\/j.peptides.2023.171051_bib46","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1432-1327.1999.00911.x","article-title":"Solution structure of a new hypothalamic neuropeptide, human hypocretin-2\/orexin-B","volume":"266","author":"Lee","year":"1999","journal-title":"Eur. J. Biochem"},{"key":"10.1016\/j.peptides.2023.171051_bib47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.peptides.2018.02.004","article-title":"Stapled truncated orexin peptides as orexin receptor agonists","volume":"102","author":"Karhu","year":"2018","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.peptides.2023.171051_bib48","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41467-021-21087-6","article-title":"Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation","volume":"12","author":"Hong","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2023.171051_bib49","unstructured":"M. Yanagisawa, Small-molecule agonists for type-2 orexin receptor, 2010. Patent US20100150840A1."},{"issue":"6","key":"10.1016\/j.peptides.2023.171051_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178526","article-title":"Orexin receptor agonist Yan 7874 is a weak agonist of orexin\/hypocretin receptors and shows orexin receptor-independent cytotoxicity","volume":"12","author":"Turku","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2023.171051_bib51","unstructured":"J. De Brabander, D. Rosenbaum, Q. Liang, W. Wang, Ox2r compounds, 2019. Patent WO2019191327A1."},{"key":"10.1016\/j.peptides.2023.171051_bib52","unstructured":"M. Cano, P.M. Grima, A. Palomer Benet, 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione Compounds Having Orexin 2 Receptor Agonist Activity, 2014. Patent WO2014198880A1."},{"key":"10.1016\/j.peptides.2023.171051_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2018.09.003","article-title":"Pharmacological characterization of the orexin\/hypocretin receptor agonist Nag 26","volume":"837","author":"Rinne","year":"2018","journal-title":"Eur. J. Pharm."},{"issue":"22","key":"10.1016\/j.peptides.2023.171051_bib54","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.peptides.2023.171051_bib55","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ALN.0000000000002161","article-title":"Nonpeptide orexin-2 receptor agonist attenuates morphine-induced sedative effects in rats","volume":"128","author":"Toyama","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.peptides.2023.171051_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172794","article-title":"TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice","volume":"187","author":"Yukitake","year":"2019","journal-title":"Pharm. Biochem Behav."},{"key":"10.1016\/j.peptides.2023.171051_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13878","article-title":"Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals","author":"Evans","year":"2023","journal-title":"J. Sleep. Res"},{"key":"10.1016\/j.peptides.2023.171051_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173464","article-title":"Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model","volume":"220","author":"Ishikawa","year":"2022","journal-title":"Pharm. Biochem Behav."},{"issue":"35","key":"10.1016\/j.peptides.2023.171051_bib59","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.peptides.2023.171051_bib60","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.122.001449","article-title":"TAK-994, a novel orally available brain-penetrant orexin 2 receptor-selective agonist, suppresses fragmentation of wakefulness and cataplexy-like episodes in mouse models of narcolepsy","author":"Ishikawa","year":"2023","journal-title":"J. Pharm. Exp. Ther. Press"},{"issue":"1","key":"10.1016\/j.peptides.2023.171051_bib61","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1038\/s41467-022-30601-3","article-title":"Molecular mechanism of the wake-promoting agent TAK-925","volume":"13","author":"Yin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2023.171051_bib62","unstructured":"M. Yanagisawa, H. Nagase, T. Saitoh, Y. Irukayama, Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof, 2016. Patent WO2016133160A1."},{"key":"10.1016\/j.peptides.2023.171051_bib63","unstructured":"H. Nagase, M. Yanagisawa, T. Saitoh, N. Kutsumura, Y. Irukayama, Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof, 2016. Patent WO2016199906A1."},{"key":"10.1016\/j.peptides.2023.171051_bib64","unstructured":"M. Daini, Y. Miyanohana, S. Mikami, Y. Kajita, M. Ogino, T. Koike, K. Takeuchi, Substituted pyrrolidine compound and use thereof, 2018. Patent WO2018164191A1."},{"key":"10.1016\/j.peptides.2023.171051_bib65","unstructured":"S. Mikami, M. Daini, Y. Miyanohana, H. Suzuki, K. Shimokawa, Y. Kajita, M. Ogino, T. Koike, K. Takeuchi, Substituted pyrrolidine compound and use thereof, 2018. Patent WO2018164192A1."},{"key":"10.1016\/j.peptides.2023.171051_bib66","unstructured":"H. Nagase, T. Saitoh, M. Yanagisawa, Y. Irukayama, Sulfonamide derivative or pharmaceutically acceptable acid-addition salt thereof, 2018. Patent WO2019117148A1."},{"key":"10.1016\/j.peptides.2023.171051_bib67","unstructured":"H. Nagase, T. Saitoh, M. Yanagisawa, Y. Irukayama, Tetralin derivative or pharmaceutically acceptable acid addition salt thereof, 2021. Patent WO2021065893A1."},{"key":"10.1016\/j.peptides.2023.171051_bib68","unstructured":"Y. Zhang, D. Zhang, Arylsulfoxamides as orexin receptor agonists, 2022. Patent WO2022187231A1."},{"key":"10.1016\/j.peptides.2023.171051_bib69","unstructured":"T. Fujimoto, K. Fukuda, H. Sugimoto, K. Rikimaru, Y. Banno, T. Matsumoto, et al. Heterocyclic compound and application thereof, 2018. Patent WO2020004536A1."},{"key":"10.1016\/j.peptides.2023.171051_bib70","unstructured":"T. Oda, Y. Ito, T. Miyazaki, K. Takeuchi, N. Tokunaga, Y. Hoashi, et al. Heterocyclic compound and use thereof, 2019. Patent WO2020004537A1."},{"key":"10.1016\/j.peptides.2023.171051_bib71","unstructured":"Y. Hattori, Y. Miyanohana, Y. Kajita, T. Koike, Y. Hoashi, N. Tokunaga, et al. Heterocyclic compound and use thereof, 2020. Patent WO2020158958A1."},{"key":"10.1016\/j.peptides.2023.171051_bib72","unstructured":"S.L. Bogen, D.J. Clausen, D.G. Duiadeen, M.T. Rudd, D. Yang, 5-alkyl pyrrolidine orexin receptor agonists, 2020. Patent WO2020167706A1."},{"key":"10.1016\/j.peptides.2023.171051_bib73","unstructured":"L.D. Pennington, Y. Choi, H. Huynh, B.M. Aquila, I.A. Mugge, Y. Hu, et al. Substituted macrocyclic compounds and related methods of treatment, 2020. Patent WO2021108628A1."},{"key":"10.1016\/j.peptides.2023.171051_bib74","unstructured":"Y. Ito, Y. Miyanohana, Y. Kajita, Y. Hoashi, Y. Hattori, T. Koike, et al. Heterocyclic compound, 2020. Patent WO2021106975A1."},{"key":"10.1016\/j.peptides.2023.171051_bib75","unstructured":"S.L. Bogen, D.J. Clausen, D.G. Duiadeen, M.T. Rudd, J. Hao, Bicycloheptane pyrrolidine orexin receptor agonists, 2021. Patent WO2022040070A1."},{"key":"10.1016\/j.peptides.2023.171051_bib76","unstructured":"S.L. Bogen, P. Chen, D.J. Clausen, X. Huang, M.T.M.T. Rudd, S.P. Walsh, et al. 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists, 2021. Patent WO2022119888A1."},{"key":"10.1016\/j.peptides.2023.171051_bib77","unstructured":"L.D. Pennington, Y. Choi, H. Huynh, B.M. Aquila, I.A. Mugge, Y. Hu, et al. Substituted macrocyclic compounds and related methods of treatment, 2021. Patent WO2022140316A1."},{"key":"10.1016\/j.peptides.2023.171051_bib78","unstructured":"L.D. Pennington, Y. Choi, H. Huynh, B.M. Aquila, I.A. Mugge, Y. Hu, et al. Substituted piperidino compounds and related methods of treatment, 2021. Patent WO2022140317A1."},{"key":"10.1016\/j.peptides.2023.171051_bib79","unstructured":"Y. Choi, Y. Hu, H. Huynh, B.M. Aquila, B.K. Raymer, I.A. Mugge, et al. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity, 2022. Patent WO2022232025A1."},{"key":"10.1016\/j.peptides.2023.171051_bib80","unstructured":"H. Huynh, L.D. Pennington, Y. Choi, B.M. Aquila, I.A. Mugge, Y. Hu, et al. Substituted fused bicyclic macrocyclic compounds and related methods of treatment, 2022. Patent WO2022251302A1."},{"key":"10.1016\/j.peptides.2023.171051_bib81","unstructured":"L.D. Pennington, Y. Choi, H. Huynh, B.M. Aquila, I.A. Mugge, Y. Hu, et al. Substituted carbamate macrocyclic compounds and related methods of treatment, 2022. Patent WO2022251304A1."},{"key":"10.1016\/j.peptides.2023.171051_bib82","unstructured":"D. Marinelli, P. Chovatia, C. Beato, G. Ouvry, Sulfonamide orexin receptor agonists and uses thereof, 2022. Patent WO2022269049A1."},{"key":"10.1016\/j.peptides.2023.171051_bib83","unstructured":"E. Ideue, M. Komiya, S. Lee, S. Uesugi, Y. Funakoshi, Cycloalkylurea derivative, 2020. Patent WO2021107023A1."},{"key":"10.1016\/j.peptides.2023.171051_bib84","unstructured":"K.A. Armacost, M.I. Chiriac, D.M. Hurzy, J.C. Kern, J. Liu, P.J. Manley, et al. Macrocyclic urea orexin receptor agonists, 2021. Patent WO2022094012A1."},{"key":"10.1016\/j.peptides.2023.171051_bib85","unstructured":"K.A. Armacost, M.I. Chiriac, D.M. Hurzy, J.C. Kern, J. Liu, P.J. Manley, et al. Urea orexin receptor agonists, 2021. Patent WO2022132696A1."},{"issue":"12","key":"10.1016\/j.peptides.2023.171051_bib86","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1021\/acs.jmedchem.1c00841","article-title":"Discovery of arylsulfonamides as dual orexin receptor agonists","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2023.171051_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128555","article-title":"Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring","volume":"60","author":"Iio","year":"2022","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"8","key":"10.1016\/j.peptides.2023.171051_bib88","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1021\/acs.jmedchem.2c01773","article-title":"Design and synthesis of orexin 1 receptor-selective agonists","volume":"66","author":"Iio","year":"2023","journal-title":"J. Med Chem."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978123001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978123001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:35:20Z","timestamp":1759311320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978123001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":87,"alternative-id":["S0196978123001146"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2023.171051","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The present and future of synthetic orexin receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2023.171051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"171051"}}